BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26640226)

  • 1. Calreticulin mRNA expression and clinicopathological characteristics in acute myeloid leukemia.
    Park S; Huh HJ; Mun YC; Seong CM; Chung WS; Chung HS; Huh J
    Cancer Genet; 2015 Dec; 208(12):630-5. PubMed ID: 26640226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.
    Wang J; Hao J; He N; Ji C; Ma D
    Turk J Haematol; 2016 Sep; 33(3):180-6. PubMed ID: 26377485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase-dependent cleavage of calreticulin in AML patients.
    Mans S; Banz Y; Mueller BU; Pabst T
    Blood; 2012 Sep; 120(13):2690-9. PubMed ID: 22915645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
    Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
    Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
    Mózes R; Gángó A; Sulák A; Vida L; Reiniger L; Timár B; Krenács T; Alizadeh H; Masszi T; Gaál-Weisinger J; Demeter J; Csomor J; Matolcsy A; Kajtár B; Bödör C
    Pathology; 2019 Apr; 51(3):301-307. PubMed ID: 30606612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
    Elala YC; Lasho TL; Gangat N; Finke C; Barraco D; Haider M; Abou Hussein AK; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
    Am J Hematol; 2016 May; 91(5):503-6. PubMed ID: 26890983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.
    Tefferi A; Nicolosi M; Mudireddy M; Szuber N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Mannarelli C; Fanelli T; Guglielmelli P; Vannucchi AM
    Am J Hematol; 2018 Mar; 93(3):348-355. PubMed ID: 29164670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the unfolded protein response is associated with favorable prognosis in acute myeloid leukemia.
    Schardt JA; Weber D; Eyholzer M; Mueller BU; Pabst T
    Clin Cancer Res; 2009 Jun; 15(11):3834-41. PubMed ID: 19470730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CALR mutation screening in pediatric primary myelofibrosis.
    An W; Wan Y; Guo Y; Chen X; Ren Y; Zhang J; Chang L; Wei W; Zhang P; Zhu X
    Pediatr Blood Cancer; 2014 Dec; 61(12):2256-62. PubMed ID: 25176567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the unfolded protein response in human acute myeloid leukemia.
    Schardt JA; Mueller BU; Pabst T
    Methods Enzymol; 2011; 489():227-43. PubMed ID: 21266233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics.
    Zhang TJ; Zhou JD; Ma JC; Deng ZQ; Qian Z; Yao DM; Yang J; Li XX; Lin J; Qian J
    Clin Chem Lab Med; 2017 Jan; 55(1):123-131. PubMed ID: 27305704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
    Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
    Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant specific anti calreticulin antibody (CAL2) immunohistochemistry as a screening test for calreticulin (CALR) mutation testing.
    Rahman K; Chandra D; Singh MK; Gupta R; Sharma A; Paul P; Kumar S; Sharma S; Nityanand S
    Int J Lab Hematol; 2020 Oct; 42(5):604-611. PubMed ID: 32463176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF3R and CALR mutations in paediatric myeloid disorders and the association of CSF3R mutations with translocations, including t(8; 21).
    Sano H; Ohki K; Park MJ; Shiba N; Hara Y; Sotomatsu M; Tomizawa D; Taga T; Kiyokawa N; Tawa A; Horibe K; Adachi S; Hayashi Y
    Br J Haematol; 2015 Aug; 170(3):391-7. PubMed ID: 25858548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
    Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
    BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
    Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
    Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
    Kourie HR; Ameye L; Paesmans M; Bron D
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):264-8. PubMed ID: 26935576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
    Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK2 -negative myeloproliferative neoplasms.
    Wojtaszewska M; Iwoła M; Lewandowski K
    Acta Haematol; 2015; 133(2):193-8. PubMed ID: 25323779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.